IGBA國際貿易與智慧財產委員會，致力於為全球學名藥及生物相似藥產業發展更具競爭性的商業環境，亦促進均衡施行、運作完善及透明化的智慧財產法制。

其目的為促進及推廣學名藥及生物相似藥之使用，以提高其市場滲透率，並透過消除貿易障礙、調和法規、降低行政負擔等相關的成本，以在智慧財產權保護與公共健康需求間達成合理的平衡，最終目標是儘早在適當的機會引入市場，為病患提供即時且節省成本的學名藥及生物相似藥的機會。該目標亦支持該行業在新產品開發，製造及訴訟方面進行的投資的可持續性和未來增長，而這通常是將新的學名藥及生物相似藥進入國內市場所必需的。

為此，學名藥和生物相似藥產業需特別關注，並需要不同區域的協會及其會員公司間高度協作與協調。IGBA國際貿易與智慧財產權委員會，將以其全球視野為實現這些目標制定協調的戰略。

The IGBA International Trade & IP Committee aims to develop a more competitive business environment for the generic and biosimilar medicines industries around the globe. It also promotes the implementation of balanced, well-functioning and transparent intellectual property systems in all jurisdictions.

Its purpose is to foster the spread of generic and biosimilar medicines worldwide increasing their market penetration through the dismantling of barriers to trade, regulatory harmonization, reduction of costs linked to administrative burdens and red tape, and a fair balance between IPR protection and public health needs. The ultimate objective aims to bring competition to markets at the earliest appropriate opportunity which  provides patients with timely access to cost-saving generic and biosimilar medicines. This objective also supports the sustainability and future growth of investments made by the industry in new product development, manufacturing and the litigation that is generally required to bring new generic pharmaceuticals and biosimilar medicines to domestic markets.

To accomplish this, the generic and biosimilar medicines industries require particular attention and a high level of collaboration and coordination among the different regional Associations and their Member companies. The IGBA International Trade & IP Committee, by virtue of its global perspective, will develop coordinated strategies for the achievements of such goals.